[ad_1] Novartis' plan to expand the market for its anti-inflammatory drug canakinumab (Ilaris) with a cardiovascular indication have encountered a problem with the US Food and Drug Administration (FDA). Vas Narasimhan, chairman …
Read More »Plans for Canakinumab CV Indication Hit Hit Roadblock with FDA
